Future of neuroprotection in Parkinson's disease

被引:35
|
作者
Naoi, M [1 ]
Maruyama, W
机构
[1] Inst Appl Biochem, Dept Brain Sci, Gifu, Japan
[2] Natl Inst Lonev Sci, Dept Basic Gerontol, Obu, Japan
关键词
apoptosis; propargylamines; mitochondrial membrane potential; anti-apoptotic drugs; caspase; 3; glyceraldehyde 3-phosphate dehydrogenase;
D O I
10.1016/S1353-8020(01)00028-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In Parkinson's disease neuroprotective therapy to rescue dopamine neurons has been proposed. Selegiline is one of neuroprotective drug candidates, as proved by in vivo and in vitro experiments. In this paper, the mechanism underlying neuroprotection by selegiline and related propargylamines was studied against apoptosis induced by an endogenous toxin, N-methyl(R)salsolinol, synthetic 6-hydroxydopamine and peroxynitrite in dopaminergic SH-SY5Y cells. Propargylamines prevented apoptotic DNA damage, through suppression of collapse in mitochondrial membrane potential and following activation of caspase 3 and signal transduction to nuclei. These results suggest that propargylamines may rescue or protect dopamine neurons in Parkinson's disease. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:139 / 145
页数:7
相关论文
共 50 条
  • [1] Future Strategies for Neuroprotection in Parkinson's Disease
    Schapira, Anthony H. V.
    [J]. NEURODEGENERATIVE DISEASES, 2010, 7 (1-3) : 210 - 212
  • [2] Neuroprotection in Parkinson's disease
    Schapira, Anthony H., V
    [J]. PARKINSONISM & RELATED DISORDERS, 2009, 15 : S41 - S43
  • [3] Neuroprotection for Parkinson's disease
    Koller, WC
    [J]. ANNALS OF NEUROLOGY, 1998, 44 (03) : S155 - S159
  • [4] Neuroprotection in Parkinson's disease
    Montastruc, JL
    Rascol, O
    Senard, JM
    [J]. LANCET, 1996, 347 (8995): : 196 - 196
  • [5] Neuroprotection for Parkinson's disease
    LeWitt, P. A.
    [J]. JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2006, (71): : 113 - 122
  • [6] Neuroprotection in Parkinson's disease
    Korlipara, LVP
    Schapira, AHV
    [J]. MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE, 2002, 51 : 373 - 378
  • [7] COMT inhibition in the treatment of Parkinson's disease: Neuroprotection and future perspectives
    Kostic, VS
    [J]. FRONTIERS IN CLINICAL NEUROSCIENCE: NEURODEGENERATION AND NEUROPROTECTION: A SYMPOSIUM IN ABEL LAJTHA'S HONOUR, 2004, 541 : 75 - 90
  • [8] Neuroprotection and Disease Modification in Parkinson's Disease
    Otero-Losada, Matilde
    Gubellini, Paolo
    Capani, Francisco
    Perez-Lloret, Santiago
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [9] Progress in neuroprotection in Parkinson's disease
    Schapira, A. H. V.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 5 - 13
  • [10] Neuroprotection in Parkinson's disease; a commentary
    Mabel Gatto, Emilia
    Riobo, Natalia
    Cecilia Carreras, Maria
    Jose Poderoso, Juan
    Micheli, Federico E.
    [J]. NEUROTOXICITY RESEARCH, 2002, 4 (02) : 141 - 145